David A. Siegel Morpho Sys Ag Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$8.6 - $18.18 $418,820 - $885,366
48,700 Added 150.77%
81,000 $1.47 Million
Q4 2023

Feb 14, 2024
BUY
$4.55 - $9.9 $146,965 - $319,770
32,300 New
32,300 $319,000
Q2 2023

Aug 14, 2023
BUY
$3.95 - $7.74 $40,290 - $78,948
10,200 New
10,200 $76,000

Others Institutions Holding MOR

# of Institutions
13
Shares Held
1.8M
Call Options Held
0
Put Options Held
14.7K
View Full List

About MorphoSys AG

MOR Quotes by TradingView
  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email